Ivo Strebel

Ivo Strebel

Auto-generated profile, based on publicly available information

Ivo Strebel

University Hospital Basel, University of Basel

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Circulation
Verified
Journal Article
Closed access
Jasper BoeddinghausJasper Boeddinghaus
Jasper Boeddinghaus
DDDimitrios Doudesis
Dimitrios Doudesis
PAPedro Lopez Ayala
Pedro Lopez Ayala
KLKuan Ken Lee
Kuan Ken Lee
LKLuca Koechlin
Luca Koechlin
AEArnold von Eckardstein
Arnold von Eckardstein
BACKGROUND: Collaboration for the Diagnosis and Evaluation of Acute Coronary Syndrome (CoDE-ACS) is a validated clinical decision support tool that uses machine learning with or without serial cardiac troponin measurements at a flexible time point to calculate the probability of myocardial infarction (MI). How CoDE-ACS performs at different time points for serial measurement and compares with guideline-recommended diagnostic pathways that rely on fixed thresholds and time points is uncertain. METHODS: Patients with possible MI without ST-segment–elevation were enrolled at 12 sites in 5 countries and underwent serial high-sensitivity cardiac troponin I concentration measurement at 0, 1, and 2 hours. Diagnostic performance of the CoDE-ACS model at each time point was determined for index type 1 MI and the effectiveness of previously validated low- and high-probability scores compared with guideline-recommended European Society of Cardiology (ESC) 0/1-hour, ESC 0/2-hour, and High-STEACS (High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome) pathways. RESULTS: In total, 4105 patients (mean age, 61 years [interquartile range, 50–74]; 32% women) were included, among whom 575 (14%) had type 1 MI. At presentation, CoDE-ACS identified 56% of patients as low probability, with a negative predictive value and sensitivity of 99.7% (95% CI, 99.5%–99.9%) and 99.0% (98.6%–99.2%), ruling out more patients than the ESC 0-hour and High-STEACS (25% and 35%) pathways. Incorporating a second cardiac troponin measurement, CoDE-ACS identified 65% or 68% of patients as low probability at 1 or 2 hours, for an identical negative predictive value of 99.7% (99.5%–99.9%); 19% or 18% as high probability, with a positive predictive value of 64.9% (63.5%–66.4%) and 68.8% (67.3%–70.1%); and 16% or 14% as intermediate probability. In comparison, after serial measurements, the ESC 0/1-hour, ESC 0/2-hour, and High-STEACS pathways identified 49%, 53%, and 71% of patients as low risk, with a negative predictive value of 100% (99.9%–100%), 100% (99.9%–100%), and 99.7% (99.5%–99.8%); and 20%, 19%, or 29% as high risk, with a positive predictive value of 61.5% (60.0%–63.0%), 65.8% (64.3%–67.2%), and 48.3% (46.8%–49.8%), resulting in 31%, 28%, or 0%, who require further observation in the emergency department, respectively. CONCLUSIONS: CoDE-ACS performs consistently irrespective of the timing of serial cardiac troponin measurement, identifying more patients as low probability with comparable performance to guideline-recommended pathways for MI. Whether care guided by probabilities can improve the early diagnosis of MI requires prospective evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00470587.

1 January 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
JWJoan Walter
Joan Walter
YTYunus Tanglay
Yunus Tanglay
JLJeanne du Fay de Lavallaz
Jeanne du Fay de Lavallaz
ISIvo Strebel
Ivo Strebel
JBJasper Boeddinghaus
Jasper Boeddinghaus
CMChristian Müller
Christian Müller

1 October 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
JLJeanne du Fay de Lavallaz
Jeanne du Fay de Lavallaz
PBPatrick Badertscher
Patrick Badertscher
TNThomas Nestelberger
Thomas Nestelberger
RIRahel Isenrich
Rahel Isenrich
ÒMÒscar Miró
Òscar Miró
SOStefan Osswald
Stefan Osswald

1 February 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
ISIvo Strebel
Ivo Strebel
RTRaphael Twerenbold
Raphael Twerenbold
DWDesiree Wussler
Desiree Wussler
JBJasper Boeddinghaus
Jasper Boeddinghaus
TNThomas Nestelberger
Thomas Nestelberger
TRTobias Reichlin
Tobias Reichlin

29 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MHMatthias Haegele
Matthias Haegele
ADAleksandar Djurdjevic
Aleksandar Djurdjevic
FJFabian Jordan
Fabian Jordan
YLYu-Ching Liu
Yu-Ching Liu
LMLeonie Mildner
Leonie Mildner
OPOtmar Pfister
Otmar Pfister
In 2019 the European Society of Cardiology (ESC) lowered the target values for low-density lipoprotein cholesterol (LDL-C) from <1.8 mmol/L to <1.4 mmol/L for secondary prevention of cardiovascular disease (CVD). The aim of this study was to determine the clinical impact of the 2019 ESC/EAS dyslipidaemia guidelines on lipid-lowering therapies and achievement rates of LDL-C targets in a contemporary cohort of CAD patients participating in an ambulatory cardiac rehabilitation (CR) program.We conducted a retrospective analysis of prospectively collected data from the Swiss Secondary Prevention Registry (SwissPR) in patients with Coronary Artery Disease (CAD), who completed the ambulatory cardiovascular rehabilitation program (CR) of the University Hospital Basel, Switzerland from January 2017 to April 2021. To evaluate the impact of the guideline publication, the cohort was split into a pre-Guideline 2019 group (A) and a post-Guideline 2019 group (B). In total 1320 patients were screened leaving 875 patients for analysis. At discharge, more patients in group B were on maximal statin doses (20% vs. 9%, p < 0.0001) and on combination therapy with ezetimibe (51% vs. 17%, p < 0.0001) than in group A, which resulted in 53% of patients reaching the LDL-C target of 50% of the LDL-C target <1.4 mmol/L in CAD patients participating in ambulatory CR.

1 June 2022 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
TBTobias Breidthardt
Tobias Breidthardt
WDWilliam van Doorn
William van Doorn
NLNoreen van der Linden
Noreen van der Linden
MDMatthias Diebold
Matthias Diebold
DWDesiree Nadine Wussler
Desiree Nadine Wussler
CMChristian Müller
Christian Müller
Background: Current guidelines recommend interpreting concentrations of NPs (natriuretic peptides) irrespective of the time of presentation to the emergency department. We hypothesized that diurnal variations in NP concentration may affect their diagnostic accuracy for acute heart failure. Methods: In a secondary analysis of a multicenter diagnostic study enrolling patients presenting with acute dyspnea to the emergency department and using central adjudication of the final diagnosis by 2 independent cardiologists, the diagnostic accuracy for acute heart failure of BNP (B-type NP), NT-proBNP (N-terminal pro-B-type NP), and MR-proANP (midregional pro-atrial NP) was compared among 1577 daytime presenters versus 908 evening/nighttime presenters. In a validation study, the presence of a diurnal rhythm in BNP and NT-proBNP concentrations was examined by hourly measurements in 44 stable individuals. Results: Among patients adjudicated to have acute heart failure, BNP, NT-proBNP, and MR-proANP concentrations were comparable among daytime versus evening/nighttime presenters (all P =nonsignificant). Contrastingly, among patients adjudicated to have other causes of dyspnea, evening/nighttime presenters had lower BNP (median, 44 [18–110] versus 74 [27–168] ng/L; P <0.01) and NT-proBNP (median, 212 [72–581] versus 297 [102–902] ng/L; P <0.01) concentrations versus daytime presenters. This resulted in higher diagnostic accuracy as quantified by the area under the curve of BNP and NT-proBNP among evening/nighttime presenters (0.97 [95% CI, 0.95–0.98] and 0.95 [95% CI, 0.93–0.96] versus 0.94 [95% CI, 0.92–0.95] and 0.91 [95% CI, 0.90–0.93]) among daytime presenters (both P <0.01). These differences were not observed for MR-proANP. Diurnal variation of BNP and NT-proBNP with lower evening/nighttime concentration was confirmed in 44 stable individuals ( P <0.01). Conclusions: BNP and NT-proBNP, but not MR-proANP, exhibit a diurnal rhythm that results in even higher diagnostic accuracy among evening/nighttime presenters versus daytime presenters. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT01831115, NCT02091427, and NCT02210897.